(Q38247190)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

0 references

1 reference

title

Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Virginia Bosó

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

L Rojas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

I Neumann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

J Reig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

J Luis Poveda

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

J Megías

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

S Bea

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

S F Aliño

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

9 September 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

The Pharmacogenomics Journal

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

38-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

The role of tacrolimus in renal transplantation

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Once- versus twice-daily tacrolimus: are the formulations truly equivalent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Why we need a broad perspective on meta-analysis. It may be crucially important for patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Estimating the mean and variance from the median, range, and the size of a sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and recipient genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.38

Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients

21 January 2018

1 reference

12 December 2020

The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients

1 reference

12 December 2020

The genetic determinants of the CYP3A5 polymorphism

1 reference

12 December 2020

Tacrolimus-induced nephrotoxicity and genetic variability: a review

1 reference

12 December 2020

Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients

1 reference

12 December 2020

Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients

1 reference

12 December 2020

Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study

1 reference

12 December 2020

Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.

1 reference

12 December 2020

CYP3A5 genetic polymorphisms in different ethnic populations

1 reference

12 December 2020

Optimization of initial tacrolimus dose using pharmacogenetic testing

1 reference

12 December 2020

CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients

1 reference

12 December 2020

Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms

1 reference

12 December 2020

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

1 reference

12 December 2020

Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids

1 reference

12 December 2020

Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation

1 reference

12 December 2020

Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors

1 reference

12 December 2020

Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes

1 reference

12 December 2020

Identifiers

DOI

10.1038/TPJ.2014.38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

16 February 2020

1052233424

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201288%20AND%20SRC:MED&resulttype=core&format=json